Trials / Completed
CompletedNCT00664625
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-791325 | Capsules, Oral, Once Daily, Single Dose |
| DRUG | Placebo | Capsules, Oral, Once Daily, Single Dose |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2008-04-23
- Last updated
- 2015-10-09
Locations
6 sites across 2 countries: United States, Argentina
Source: ClinicalTrials.gov record NCT00664625. Inclusion in this directory is not an endorsement.